Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT)
when added to angiotensin‐converting enzyme inhibitor (ACEi) alone in patients with heart …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Abstract Background The Valsartan Heart Failure Trial (Val‐HeFT) is the first large‐scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …

Although a cornerstone in the treatment of heart failure, angiotensin-converting enzyme
inhibitors are under-used, partly due to side effects. If proven at least similarly efficacious to …

The aims of the treatment of heart failure are to improve the quality of life and slow the
progression of cardiac disease. Improvement of quality of life is best assessed by …

Objective: To evaluate the effect on cardiac hemodynamic parameters of valsartan in
patients with chronic stable congestive heart failure previously untreated with ACE inhibitors …

Background: To investigate the role of persistent angiotensin activity despite
angiotensinconverting enzyme inhibitor therapy in the progression of heart failure, the …

Angiotensin‐converting enzyme (ACE) inhibitors have a central role in the management of
heart failure, reflecting the contribution of the renin‐angiotensin‐aldosterone system to the …

BACKGROUND: Whether an angiotensin receptor blocker is of benefit when added to a full
dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain …